Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ernexa Therapeutics (ERNA) EBT (2016 - 2025)

Historic EBT for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Ernexa Therapeutics' EBT rose 9535.95% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.3 million, marking a year-over-year increase of 5918.79%. This contributed to the annual value of -$44.5 million for FY2024, which is 10547.74% down from last year.
  • As of Q3 2025, Ernexa Therapeutics' EBT stood at -$1.2 million, which was up 9535.95% from -$3.1 million recorded in Q2 2025.
  • Over the past 5 years, Ernexa Therapeutics' EBT peaked at -$1.2 million during Q3 2025, and registered a low of -$86.0 million during Q3 2021.
  • Over the past 5 years, Ernexa Therapeutics' median EBT value was -$5.8 million (recorded in 2024), while the average stood at -$12.2 million.
  • In the last 5 years, Ernexa Therapeutics' EBT plummeted by 563240.0% in 2021 and then skyrocketed by 9535.95% in 2025.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' EBT stood at -$86.0 million in 2021, then skyrocketed by 94.83% to -$4.4 million in 2022, then crashed by 38.39% to -$6.2 million in 2023, then rose by 6.32% to -$5.8 million in 2024, then soared by 78.61% to -$1.2 million in 2025.
  • Its EBT stands at -$1.2 million for Q3 2025, versus -$3.1 million for Q2 2025 and -$8.2 million for Q1 2025.